查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1855057

类器官和球状体的全球市场:各类型，各来源，各用途，各终端用户，各地区-市场规模，产业动态，机会分析，预测(2025年～2033年)

Global Organoids And Spheroids Market: By Type, Source, Application, End-User, Region- Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 433 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

受对更精确的疾病和组织三维模型的需求不断增长的推动，类器官和球状体市场正经历显着增长。因此，到 2024 年，市场规模已达到约 10.7258 亿美元，反映出这些技术的强劲应用和投资。展望未来，预计该市场将快速扩张，到 2033 年的估值将达到 66.1397 亿美元。这一增长意味着 2025 年至 2033 年预测期内的复合年增长率 (CAGR) 为 22.4%。多种因素正在推动这一强劲成长。

监管机构越来越支持在研究和测试中使用非动物模型，这使得类器官和球状体作为一种符合伦理且有效的替代方案更具吸引力。此外，製药业的巨额投资正在加速这些模型的开发和应用，因为各公司都在寻求更具预测性和效率的药物测试和开发方法。

市场动态

类器官和球状体市场竞争激烈，众多参与者共同造就了充满活力的市场环境。像赛默飞世尔科技（Thermo Fisher Scientific）和默克集团（Merck KGaA）这样的老牌公司凭藉其雄厚的资源和丰富的产品线，拥有巨大的市场影响力。除了这些行业领导者之外，像STEMCELL Technologies和InSphero AG这样的专业公司专注于细分领域，为类器官和球状体领域提供针对性的解决方案，并推广特定的应用。

为了巩固其市场地位，默克集团于2024年12月收购了HUB Organoids。此次收购为默克的产品组合新增了70种经过验证的类器官模型，并增强了其为科研提供多样化、可靠的生物模型的能力。凭藉这一发展势头，默克公司于2025年5月与IMEC合作，共同开发一个能够同时分析1000个类器官的尖端平台。此次合作旨在显着提高类器官研究的通量和效率，并体现了该领域向高通量、可扩展技术发展的持续趋势。

成长驱动因素

类器官和球状体市场正迅速从传统的生物医学研究扩展到化妆品和化学品安全测试等新的应用领域。这一转变在很大程度上是由日益严格的法规推动的，这些法规旨在减少或消除动物试验——动物试验曾是评估产品安全性的标准方法。为了应对这些监管压力，企业正扩大采用先进的3D类器官模型——尤其是皮肤和眼部类器官——这些模型为毒性和安全性评估提供了更符合伦理、更准确、更贴近人体的替代方案。欧莱雅2024年的愿景就是这一趋势的一个典型例证，该愿景旨在将皮肤类器官的年产量提升至惊人的10万个。这些类器官被广泛用于毒理学筛选，以评估化妆品成分和配方的安全性和有效性。

新兴商业机会趋势

在类器官智慧（也称为生物运算）这个新兴领域，随着研究人员利用脑类器官的运算能力，突破性的、面向未来的商业机会正在涌现。这种创新方法探索了利用活体神经组织作为生物处理器的潜力，有望彻底改变我们对运算和人工智慧的认知。 2024年，约翰霍普金斯大学的一个计画取得了显着进展，获得了50万美元的初始资金，用于开发由1万个相互连接的脑类器官组成的生物电脑。这项投资凸显了人们对基于类器官的计算系统执行复杂资讯处理任务的潜力的日益增长的信心。

优化障碍

类器官球体市场面临的一大挑战是这些3D模型缺乏血管，这大大限制了它们在长期功能研究中的应用。血管生成，即血管的形成，对于活体组织中营养物质、氧气的输送和代谢废物的清除至关重要。如果没有这种复杂的血管网络，类器官和球体就难以长期维持其活性和功能，这限制了它们模拟完全发育器官生理条件的能力。这种限制阻碍了研究人员进行长期实验的能力，而这些实验对于理解慢性疾病、药物代谢和长期治疗效果至关重要。

目录

第1章 调查架构

  • 调查目的
  • 产品概要
  • 市场区隔

第2章 调查手法

  • 定性调查
    • 一级资讯来源·二级资讯来源
  • 定量调查
    • 一级资讯来源·二级资讯来源
  • 初步调查受访者的明细:各地区
  • 调查的前提
  • 市场规模·估计
  • 资料三角测量

第3章 摘要整理:类器官和球状体的全球市场

第4章 全球类器官和球状体市场概要

  • 产业价值链分析
    • 厂商
    • 供应商
    • 终端用户
  • 产业的展望
  • 大环境分析
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商业者的威胁
    • 竞争的程度
  • 市场动态和趋势
    • 成长促进因素
    • 阻碍因素
    • 课题
    • 主要趋势
  • COVID-19对市场成长趋势的影响评估
  • 市场成长与展望
    • 市场收益估计·预测，2020年～2033年
    • 价格趋势分析
  • 竞争仪表板
    • 市场集中率
    • 企业占有率分析(金额%)、2024年
    • 竞争製图

第5章 类器官和球状体的全球市场分析:各类型

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 类器官
    • 球状体

第6章 类器官和球状体的全球市场分析:各方法

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 类器官
    • 球状体

第7章 类器官和球状体的全球市场分析:各来源

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 类器官
    • 球状体

第8章 类器官和球状体的全球市场分析:各用途

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 发生生物学
    • 个人化医疗
    • 再生医疗
    • 疾病病理学研究
    • 医药品的毒性·有效性实验

第9章 类器官和球状体的全球市场分析:各终端用户

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 生物科技·製药产业
    • 学术·研究机关
    • 医院·诊断中心

第10章 类器官和球状体的全球市场分析:各地区

  • 主要洞察
  • 市场规模·预测，2020年～2033年
    • 北美
    • 欧洲
    • 亚太地区
    • 中东·非洲
    • 南美

第11章 北美的类器官和球状体市场分析

第12章 欧洲的类器官和球状体市场分析

第13章 亚太地区的类器官和球状体市场分析

第14章 中东·非洲的类器官和球状体市场分析

第15章 南美的类器官和球状体市场分析

第16章 美国的类器官和球状体市场分析

第17章 加拿大的类器官和球状体市场分析

第18章 墨西哥的类器官和球状体市场分析

第19章 英国的类器官和球状体市场分析

第20章 德国的类器官和球状体市场分析

第21章 法国的类器官和球状体市场分析

第22章 义大利的类器官和球状体市场分析

第23章 西班牙的类器官和球状体市场分析

第24章 波兰的类器官和球状体市场分析

第25章 俄罗斯的类器官和球状体市场分析

第26章 其他欧洲的类器官和球状体市场分析

第27章 日本的类器官和球状体市场分析

第28章 企业简介

  • 3D BioMatrix
  • 3D Biotek LLC
  • AMS Biotechnology(Europe)Limited
  • ATCC
  • Cellesce Ltd
  • Corning Incorporated
  • Greiner Bio-One
  • Hubrecht Organoid Technology(HUB)
  • InSphero/Perkin Elmer
  • Kuraray
  • Lonza
  • Merck KGaA
  • Prellis Biologics
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific, Inc.
  • 其他的主要企业
简介目录
Product Code: AA0423422

The organoids and spheroids market is experiencing significant growth driven by the increasing demand for more accurate three-dimensional models of diseases and tissues. As a result, the market size reached approximately US$ 1,072.58 million in 2024, reflecting strong adoption and investment in these technologies. Looking ahead, the market is projected to expand rapidly, with an estimated valuation of US$ 6,613.97 million by 2033. This growth translates to a compound annual growth rate (CAGR) of 22.4% over the forecast period from 2025 to 2033. Several factors are driving this robust expansion.

Regulatory agencies are increasingly supporting the use of non-animal models for research and testing, which elevates the appeal of organoids and spheroids as ethical and effective alternatives. Additionally, substantial investments from the pharmaceutical industry are accelerating the development and application of these models, as companies seek more predictive and efficient methods for drug testing and development.

Noteworthy Market Developments

The organoids and spheroids market is characterized by intense competition, with a diverse range of players contributing to its dynamic landscape. Large, well-established corporations such as Thermo Fisher Scientific and Merck KGaA hold significant influence due to their extensive resources and broad product offerings. Alongside these industry giants, specialized companies like STEMCELL Technologies and InSphero AG focus on niche areas, providing targeted solutions and advancing specific applications within the organoid and spheroid space.

In a strategic move to strengthen its position, Merck KGaA acquired HUB Organoids in December 2024. This acquisition expanded Merck's portfolio by adding 70 validated organoid models, enhancing its capabilities in providing diverse and reliable biological models for research. Building on this momentum, Merck entered into a partnership with IMEC in May 2025 to develop a cutting-edge platform designed to analyze 1,000 organoids simultaneously. This collaboration aims to significantly increase throughput and efficiency in organoid research, reflecting the ongoing trend toward high-capacity, scalable technologies in the field.

Core Growth Drivers

The organoids and spheroids market is rapidly expanding beyond traditional biomedical research into new application areas such as cosmeceuticals and chemical safety testing. This shift is largely driven by increasingly stringent regulations aimed at reducing or eliminating animal testing, which has historically been the standard method for evaluating product safety. In response to these regulatory pressures, companies are increasingly adopting advanced 3D organoid models, particularly skin and eye organoids, that offer more ethical, accurate, and human-relevant alternatives for toxicity and safety assessments. A prime example of this trend is seen in L'Oreal's 2024 initiative to scale up the production of skin organoids to an impressive 100,000 units annually. These organoids are utilized extensively in toxicology screening to evaluate the safety and efficacy of cosmetic ingredients and formulations.

Emerging Opportunity Trends

A groundbreaking and futuristic opportunity is unfolding in the emerging field of Organoid Intelligence, also known as biocomputing, where researchers are leveraging the computational capabilities of brain organoids. This innovative approach explores the possibility of using living neural tissue as biological processors, potentially revolutionizing the way we think about computation and artificial intelligence. In 2024, a notable milestone was reached when a project at Johns Hopkins University secured an initial funding of US$ 500,000 to develop a biocomputer composed of 10,000 interconnected brain organoids. This investment underscores growing confidence in the potential of organoid-based computing systems to perform complex information processing tasks.

Barriers to Optimization

One of the critical challenges facing the organoids and spheroids market is the lack of vascularization within these 3D models, which significantly limits their use in long-term functional studies. Vascularization-the formation of blood vessel networks-is essential for supplying nutrients, oxygen, and removing waste products in living tissues. Without this complex vascular network, organoids and spheroids struggle to maintain viability and functionality over extended periods, which restricts their ability to mimic the physiological conditions of fully developed organs. This limitation hampers researchers' capacity to conduct prolonged experiments that are crucial for understanding chronic diseases, drug metabolism, and long-term therapeutic effects.

Detailed Market Segmentation

By Type, the organoids segment is solidifying its dominant position within the organoids and spheroids market, with projections indicating that it will account for over 53% of the total revenue share. This prominent leadership is largely attributed to organoids' advanced capacity to mimic the intricate structure and diverse functionality of human organs more accurately than other models. Unlike simpler two-dimensional cultures or even spheroids, organoids recreate the complex cellular architecture and microenvironment found in actual human tissues, making them highly valuable for a wide range of biomedical applications.

By Application, the developmental biology segment is poised to dominate the organoids and spheroids market, expected to capture a substantial 32.1% share of the overall market. This leadership position is largely attributed to the unique and unparalleled insights that these three-dimensional (3D) models provide into fundamental biological processes. Organoids and spheroids have revolutionized the study of complex phenomena such as organogenesis, embryogenesis, and tissue development by allowing researchers to observe and analyze these intricate events in a controlled and human-relevant environment.

By End Users, the pharmaceutical and biotechnology industry stands as the foremost end-user segment in the organoids and spheroids market, expected to capture more than 47.4% of the total revenue share. This dominant position is driven by the urgent demand within these industries for more predictive and human-relevant preclinical models during drug development and testing. Traditional animal models have long been the standard for evaluating drug safety and efficacy, but their limitations have become increasingly apparent. Approximately 90% of drugs fail to receive approval from regulatory bodies like the FDA, despite promising results in animal studies. This high failure rate highlights a significant efficiency gap in the drug development pipeline, causing delays, increased costs, and lost opportunities.

Segment Breakdown

By Type

  • Organoids
  • Neural Organoids
  • Hepatic Organoids
  • Intestinal Organoids
  • Kidney Organoids
  • Other Organoids
  • Spheroids
  • Multicellular tumor spheroids (MCTS)
  • Neurospheres
  • Mammospheres
  • Hepatospheres
  • Embryoid bodies

By Method

  • Organoids
  • General Submerged Method for Organoid Culture
  • Crypt Organoid Culture Techniques
  • Air Liquid Interface (ALI) Method for Organoid Culture
  • Clonal Organoids from Lgr5+ Cells
  • Brain and Retina Organoid Formation Protocol
  • Spheroids
  • Micropatterned Plates
  • Low Cell Attachment Plates
  • Hanging Drop Method
  • Others

By Source

  • Organoids
  • Primary Tissues
  • Stem Cells
  • Spheroids
  • Cell Line
  • Primary Cell
  • iPSCs Derived Cell

By Application

  • Developmental Biology
  • Personalized Medicine
  • Regenerative Medicine
  • Disease Pathology Studies
  • Drug Toxicity & Efficacy Testing

By End User

  • Biotechnology and pharmaceutical industries
  • Academic & Research Institutes
  • Hospitals and diagnostic centers

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a leading position in the organoids and spheroids market, commanding over 40.60% of the global market share. This dominance is underpinned by strong financial support and the presence of advanced research infrastructure across the region. The United States, in particular, has made significant strides in advancing organoid technology through substantial funding initiatives and regulatory advancements. In 2024, the U.S. National Cancer Institute (NCI) invested in 45 new research projects dedicated specifically to developing patient-derived cancer organoids, signaling a focused commitment to leveraging this technology for cancer research and personalized medicine.
  • Regulatory progress has also been a key factor contributing to North America's leadership. The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) launched a pilot program in 2024 aimed at qualifying five different organ-on-a-chip platforms for regulatory submissions. This initiative reflects growing recognition of organoid and microphysiological systems as valuable tools in drug development and safety assessment. Such regulatory support not only facilitates innovation but also helps streamline the pathway for organoid-based technologies to enter clinical and commercial applications.

Leading Market Participants

  • 3D BioMatrix
  • 3D Biotek LLC
  • AMS Biotechnology (Europe) Limited
  • ATCC
  • Cellesce Ltd
  • Corning Incorporated
  • Greiner Bio-One
  • Hubrecht Organoid Technology (HUB)
  • InSphero/Perkin Elmer
  • Kuraray
  • Lonza
  • Merck KGaA
  • Prellis Biologics
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific, Inc.
  • Other Prominent Players.

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Organoids and Spheroids Market

Chapter 4. Global Organoids and Spheroids Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Manufacturers
    • 4.1.2. Providers
    • 4.1.3. End User
  • 4.2. Industry Outlook
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
    • 4.7.2. Price Trend Analysis
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping

Chapter 5. Global Organoids and Spheroids Market Analysis, By Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 5.2.1. Organoids
      • 5.2.1.1. Neural Organoids
      • 5.2.1.2. Hepatic Organoids
      • 5.2.1.3. Intestinal Organoids
      • 5.2.1.4. Kidney Organoids
      • 5.2.1.5. Other Organoids
    • 5.2.2. Spheroids
      • 5.2.2.1. Multicellular tumor spheroids (MCTS)
      • 5.2.2.2. Neurospheres
      • 5.2.2.3. Mammospheres
      • 5.2.2.4. Hepatospheres
      • 5.2.2.5. Embryoid bodies

Chapter 6. Global Organoids and Spheroids Market Analysis, By Method

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 6.2.1. Organoids
      • 6.2.1.1. General Submerged Method for Organoid Culture
      • 6.2.1.2. Crypt Organoid Culture Techniques
      • 6.2.1.3. Air Liquid Interface (ALI) Method for Organoid Culture
      • 6.2.1.4. Clonal Organoids from Lgr5+ Cells
      • 6.2.1.5. Brain and Retina Organoid Formation Protocol
    • 6.2.2. Spheroids
        • 6.2.2.1.1. Micropatterned Plates
        • 6.2.2.1.2. Low Cell Attachment Plates
        • 6.2.2.1.3. Hanging Drop Method
        • 6.2.2.1.4. Others

Chapter 7. Global Organoids and Spheroids Market Analysis, By Source

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 7.2.1. Organoids
      • 7.2.1.1. Primary Tissues
      • 7.2.1.2. Stem Cells
    • 7.2.2. Spheroids
      • 7.2.2.1. Cell Line
      • 7.2.2.2. Primary Cell
      • 7.2.2.3. iPSCs Derived Cell

Chapter 8. Global Organoids and Spheroids Market Analysis, By Application

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 8.2.1. Developmental Biology
    • 8.2.2. Personalized Medicine
    • 8.2.3. Regenerative Medicine
    • 8.2.4. Disease Pathology Studies
    • 8.2.5. Drug Toxicity & Efficacy Testing

Chapter 9. Global Organoids and Spheroids Market Analysis, By End User

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. Biotechnology and pharmaceutical industries
    • 9.2.2. Academic & Research Institutes
    • 9.2.3. Hospitals and diagnostic centers

Chapter 10. Global Organoids and Spheroids Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Organoids and Spheroids Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 11.2.1. By Type
    • 11.2.2. By Method
    • 11.2.3. By Source
    • 11.2.4. By Application
    • 11.2.5. By End Use
    • 11.2.6. By Country

Chapter 12. Europe Organoids and Spheroids Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 12.2.1. By Type
    • 12.2.2. By Method
    • 12.2.3. By Source
    • 12.2.4. By Application
    • 12.2.5. By End Use
    • 12.2.6. By Country

Chapter 13. Asia Pacific Organoids and Spheroids Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 13.2.1. By Type
    • 13.2.2. By Method
    • 13.2.3. By Source
    • 13.2.4. By Application
    • 13.2.5. By End Use
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Organoids and Spheroids Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 14.2.1. By Type
    • 14.2.2. By Method
    • 14.2.3. By Source
    • 14.2.4. By Application
    • 14.2.5. By End Use
    • 14.2.6. By Country

Chapter 15. South America Organoids and Spheroids Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 15.2.1. By Type
    • 15.2.2. By Method
    • 15.2.3. By Source
    • 15.2.4. By Application
    • 15.2.5. By End Use
    • 15.2.6. By Country

Chapter 16. The US Organoids and Spheroids Market Analysis

  • 16.1. Key Insights
  • 16.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 16.2.1. By Type
    • 16.2.2. By Method
    • 16.2.3. By Source
    • 16.2.4. By Application
    • 16.2.5. By End Use

Chapter 17. Canada Organoids and Spheroids Market Analysis

  • 17.1. Key Insights
  • 17.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 17.2.1. By Type
    • 17.2.2. By Method
    • 17.2.3. By Source
    • 17.2.4. By Application
    • 17.2.5. By End Use

Chapter 18. Mexico Organoids and Spheroids Market Analysis

  • 18.1. Key Insights
  • 18.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 18.2.1. By Type
    • 18.2.2. By Method
    • 18.2.3. By Source
    • 18.2.4. By Application
    • 18.2.5. By End Use

Chapter 19. The UK Organoids and Spheroids Market Analysis

  • 19.1. Key Insights
  • 19.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 19.2.1. By Type
    • 19.2.2. By Method
    • 19.2.3. By Source
    • 19.2.4. By Application
    • 19.2.5. By End Use

Chapter 20. Germany Organoids and Spheroids Market Analysis

  • 20.1. Key Insights
  • 20.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 20.2.1. By Type
    • 20.2.2. By Method
    • 20.2.3. By Source
    • 20.2.4. By Application
    • 20.2.5. By End Use

Chapter 21. France Organoids and Spheroids Market Analysis

  • 21.1. Key Insights
  • 21.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 21.2.1. By Type
    • 21.2.2. By Method
    • 21.2.3. By Source
    • 21.2.4. By Application
    • 21.2.5. By End Use

Chapter 22. Italy Organoids and Spheroids Market Analysis

  • 22.1. Key Insights
  • 22.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 22.2.1. By Type
    • 22.2.2. By Method
    • 22.2.3. By Source
    • 22.2.4. By Application
    • 22.2.5. By End Use

Chapter 23. Spain Organoids and Spheroids Market Analysis

  • 23.1. Key Insights
  • 23.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 23.2.1. By Type
    • 23.2.2. By Method
    • 23.2.3. By Source
    • 23.2.4. By Application
    • 23.2.5. By End Use

Chapter 24. Poland Organoids and Spheroids Market Analysis

  • 24.1. Key Insights
  • 24.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 24.2.1. By Type
    • 24.2.2. By Method
    • 24.2.3. By Source
    • 24.2.4. By Application
    • 24.2.5. By End Use

Chapter 25. Russia Organoids and Spheroids Market Analysis

  • 25.1. Key Insights
  • 25.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 25.2.1. By Type
    • 25.2.2. By Method
    • 25.2.3. By Source
    • 25.2.4. By Application
    • 25.2.5. By End Use

Chapter 26. Rest of Europe Organoids and Spheroids Market Analysis

  • 26.1. Key Insights
  • 26.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 26.2.1. By Type
    • 26.2.2. By Method
    • 26.2.3. By Source
    • 26.2.4. By Application
    • 26.2.5. By End Use

Chapter 27. Japan Organoids and Spheroids Market Analysis

  • 27.1. Key Insights
  • 27.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 27.2.1. By Type
    • 27.2.2. By Method
    • 27.2.3. By Source
    • 27.2.4. By Application
    • 27.2.5. By End Use

Chapter 28. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 28.1. 3D BioMatrix
  • 28.2. 3D Biotek LLC
  • 28.3. AMS Biotechnology (Europe) Limited
  • 28.4. ATCC
  • 28.5. Cellesce Ltd
  • 28.6. Corning Incorporated
  • 28.7. Greiner Bio-One
  • 28.8. Hubrecht Organoid Technology (HUB)
  • 28.9. InSphero/Perkin Elmer
  • 28.10. Kuraray
  • 28.11. Lonza
  • 28.12. Merck KGaA
  • 28.13. Prellis Biologics
  • 28.14. STEMCELL Technologies Inc.
  • 28.15. Thermo Fisher Scientific, Inc.
  • 28.16. Other Prominent Players.